1st World Health Organization International Standard for Hepatitis D Virus RNA for Nucleic Acid Amplification Techniques (NAT)-Based Assays

PEI code 7657/12

(Version 2.1, February 2018)

1. INTENDED USE

The 1st World Health Organization (WHO) International Standard for hepatitis D virus (HDV) RNA is intended to be used in the standardization of nucleic acid amplification technique (NAT)-based assays for HDV. The establishment of an international standard is an urgent need in the standardization, harmonization and quality control of the NAT tests and patient management (1). The standard has been prepared using a genotype 1 strain of HDV, derived from the HDV positive human plasma and further diluted in human negative plasma. The material has been lyophilized in 0.5 ml aliquots and stored at -20ºC. The material has been evaluated in an international collaborative study involving 15 laboratories performing a wide range of HDV real-time NAT assays. Further details of the collaborative study are available in the report WHO/BS/2013.2227 (2). The standard is intended for calibration of secondary reference materials and for definition critical assay attributes such as analytical sensitivities in International Units (IU).

2. UNITAGE

This reagent has been assigned a unitage of 575,000 International Units/ml.

3. CONTENTS

Each vial contains 0.5 ml of lyophilized plasma containing infectious HDV.

4. CAUTION

THIS PREPARATION IS NOT FOR ADMINISTRATION TO HUMANS.

The preparation contains material of human origin, and contains infectious HDV. The reference materials has been diluted in human plasma negative for HBV DNA, HCV RNA, HDV RNA, HIV-1 RNA, HBsAg, anti-HDV, anti-HCV, and anti-HIV-1/2.

As with all materials of biological origin, this preparation should be regarded as potentially hazardous to health. It should be used and discarded according to your own laboratory’s safety procedures. Such safety procedures probably will include the wearing of protective gloves and avoiding the generation of aerosols. Care should be exercised in opening ampoules or vials, to avoid cuts.

5. USE OF MATERIAL

No attempt should be made to weigh out any portion of the freeze-dried material prior to reconstitution.

The material is supplied lyophilized and should be stored at or below -20°C. Each vial should be reconstituted in 0.5 ml of sterile nuclease-free water. The product should be reconstituted just prior to use. The international standard should be used for the calibration of secondary reference preparations for HDV RNA, in parallel. The secondary reference preparations can then be assigned a concentration in IU (3) If not all the material is used immediately, laboratories may aliquot the remaining material into suitable volumes which should be stored at or below -70°C.

6. STABILITY

As the stability studies with accelerated conditions indicate high stability of the lyophilized reference material under the recommended storage conditions (at or below -20°C), there is no expire date assigned to the international standard. This approach complies with the recommendations for the preparation, characterization and establishment of international and other biological reference standards (3). The reference material is held at the Paul-Ehrlich-Institut (PEI) within assured, temperature-controlled storage facilities. During its life cycle the stability is monitored at regular intervals. The international standard remains valid with the assigned potency and status until withdrawn or amended.

Reference materials should be stored on receipt as indicated on the label. Once, diluted or aliquoted, users should determine the stability of the material according to their own method of preparation, storage and use.

Users who have data supporting any deterioration in the characteristics of any reference preparation are encouraged to contact PEI.

7. REFERENCES


8. ACKNOWLEDGEMENTS

We are grateful to the Department of Gastroenterology of the Ankara University, Turkey for supplying the candidate materials and for their collaboration and to all study participants.

9. FURTHER INFORMATION

Further information for this material can be obtained as follows: whoccivd@pei.de or WHO Biological Reference Preparations: http://www.who.int/biologicals/en/

Paul-Ehrlich-Institut
Paul-Ehrlich-Str. 51-59
63225 Langen, Germany

A WHO Collaborating Centre
for Quality Assurance of Blood Products and
in vitro Diagnostic Devices

Email: whoccivd@pei.de
Web: http://www.pei.de
10. CUSTOMER FEEDBACK
Customers are encouraged to provide feedback on the suitability or use of the material provided or other aspects of our service. Please send any comments to whoccivd@pei.de.

11. CITATION
In any circumstance where the recipient publishes a reference to PEI materials, it is important that the correct name of the preparation, the PEI code number, the name and the address of PEI are cited correctly.

12. MATERIAL SAFETY SHEET

<table>
<thead>
<tr>
<th>Physical properties (at room temperature)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Physical appearance</td>
<td>Lyophilized powder</td>
</tr>
<tr>
<td>Fire hazard</td>
<td>None</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Chemical properties</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Stable</td>
<td>Yes</td>
</tr>
<tr>
<td>Corrosive:</td>
<td>No</td>
</tr>
<tr>
<td>Hygroscopic</td>
<td>No</td>
</tr>
<tr>
<td>Oxidising:</td>
<td>No</td>
</tr>
<tr>
<td>Flammable</td>
<td>No</td>
</tr>
<tr>
<td>Irritant:</td>
<td>No</td>
</tr>
</tbody>
</table>

| Other (specify)     | CONTAINS HUMAN PLASMA & INFECTIOUS HEPATITIS D VIRUS (HDV) |

| Handling:           | See caution, section 4 |

<table>
<thead>
<tr>
<th>Toxicological properties</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Effects of inhalation:</td>
<td>Avoid – contains infectious HDV</td>
</tr>
<tr>
<td>Effects of ingestion:</td>
<td>Avoid – contains infectious HDV</td>
</tr>
<tr>
<td>Effects of skin absorption:</td>
<td>Avoid – contains infectious HDV</td>
</tr>
</tbody>
</table>

**Suggested First Aid**

- Inhalation: Seek medical advice - contains infectious HDV
- Ingestion: Seek medical advice - contains infectious HDV
- Contact with eyes: Wash thoroughly with water. Seek medical advice – contains infectious HDV
- Contact with skin: Wash thoroughly with water. Seek medical advice – contains infectious HDV

**Action on Spillage and Method of Disposal**

Spillage of vial contents should be taken up with absorbent material wetted with an appropriate disinfectant. Rinse area with an appropriate disinfectant followed by water. Absorbent materials used to treat spillage should be treated as biological waste.

13. LIABILITY AND LOSS
Information provided by the Institute is given after the exercise of all reasonable care and skill in its compilation, preparation and issue, but it is provided without liability to the Recipient in its application and use.

It is the responsibility of the Recipient to determine the appropriateness of the materials supplied by the Institute to the Recipient (“the Goods”) for the proposed application and ensure that it has the necessary technical skills to determine that they are appropriate. Results obtained from the Goods are likely to be dependent on conditions of use by the Recipient and the variability of materials beyond the control of the Institute.

All warranties are excluded to the fullest extent permitted by law, including without limitation that the Goods are free from infectious agents or that the supply of Goods will not infringe any rights of any third party.

The Institute shall not be liable to the Recipient for any economic loss whether direct or indirect, which arise in connection with this agreement.

The total liability of the Institute in connection with this agreement, whether for negligence or breach of agreement or otherwise, shall in no event exceed 120% of any price paid or payable by the Recipient for the supply of the Goods.

If any of the Goods supplied by the Institute should prove not to meet their specification when stored and used correctly (and provided that the Recipient has returned the Goods to the Institute together with written notification of such alleged defect within seven days of the time when the Recipient discovers or ought to have discovered the defect), the Institute shall either replace the Goods or, at its sole option, refund the handling charge provided that performance of either one of the above options shall constitute an entire discharge of the Institute’s liability under this Condition.